Cargando…

Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment

INTRODUCTION: The insufficient targeting delivery of therapeutic agents greatly impeded the treatment outcomes of rheumatoid arthritis (RA). Despite the recognized therapeutic advantages of gambogic acid (GBA) in inflammatory diseases, its high delivery efficiency to inflammatory site still limits i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuling, Nie, Xin, Wu, Yihan, Lin, Longfei, Liao, Qian, Li, Jingjing, Lee, Simon Ming-Yuen, Li, Hui, Zhang, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522496/
https://www.ncbi.nlm.nih.gov/pubmed/37771407
http://dx.doi.org/10.2147/IJN.S422096
_version_ 1785110367777587200
author Liu, Yuling
Nie, Xin
Wu, Yihan
Lin, Longfei
Liao, Qian
Li, Jingjing
Lee, Simon Ming-Yuen
Li, Hui
Zhang, Jinming
author_facet Liu, Yuling
Nie, Xin
Wu, Yihan
Lin, Longfei
Liao, Qian
Li, Jingjing
Lee, Simon Ming-Yuen
Li, Hui
Zhang, Jinming
author_sort Liu, Yuling
collection PubMed
description INTRODUCTION: The insufficient targeting delivery of therapeutic agents greatly impeded the treatment outcomes of rheumatoid arthritis (RA). Despite the recognized therapeutic advantages of gambogic acid (GBA) in inflammatory diseases, its high delivery efficiency to inflammatory site still limits its clinical application. Self-assembly of drug dimers into carrier-free nanoparticles (NPs) has become a straightforward and attractive approach to develop nanomedicines for RA treatment. Herein, homodimers of GBA were designed to form the carrier-free NPs by self-assembly for RA treatment. METHODS: The synthetic gambogic acid dimers (GBA(2)) were self-assembled into NPs using a one-step solvent evaporation method. The size distribution, morphology, drug-loading efficiency (DLE) and storage stability were evaluated. A molecular dynamic simulation was conducted to gain further insight into the self-assembly mechanisms of GBA(2)/NPs. Besides, we investigated the cytotoxicity, apoptosis and cellular uptake profiles of GBA(2)/NPs in macrophages and osteoclasts. Finally, the specific biodistribution on the ankles of adjuvant-induced arthritis (AIA) mice, and the anti-RA efficacy of the AIA rat model were assessed. RESULTS: GBA(2)/NPs exhibited the uniform spherical structure, possessing excellent colloidal stability, high self-assembly stability, high drug loading and low hemolytic activity. Comparing with GBA, GBA(2)/NPs showed higher cytotoxicity, cellular uptake and apoptosis rate against osteoclasts. In addition, GBA(2)/NPs exhibited much higher accumulation in ankle joints in vivo. As expected, the systematic administration of GBA(2)/NPs resulted in the greater alleviation of arthritic symptoms, cartilage protection, and inflammation, notably the reduced systemic toxicity compared to free GBA. CONCLUSION: GBA(2)/NPs formed GBA dimers exhibited the superior accumulation in the inflamed joint and anti-RA activity, potentially attributing to the similar extravasation through leaky vasculature and subsequent inflammatory cell-mediated sequestration (“ELVIS”) effects in inflamed joint and the enhanced cellular uptake in macrophages and osteoclasts. Our findings provide substantial evidence that self-assembly of GBA(2)/NPs would be a promising therapeutic alternative for RA treatment.
format Online
Article
Text
id pubmed-10522496
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105224962023-09-28 Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment Liu, Yuling Nie, Xin Wu, Yihan Lin, Longfei Liao, Qian Li, Jingjing Lee, Simon Ming-Yuen Li, Hui Zhang, Jinming Int J Nanomedicine Original Research INTRODUCTION: The insufficient targeting delivery of therapeutic agents greatly impeded the treatment outcomes of rheumatoid arthritis (RA). Despite the recognized therapeutic advantages of gambogic acid (GBA) in inflammatory diseases, its high delivery efficiency to inflammatory site still limits its clinical application. Self-assembly of drug dimers into carrier-free nanoparticles (NPs) has become a straightforward and attractive approach to develop nanomedicines for RA treatment. Herein, homodimers of GBA were designed to form the carrier-free NPs by self-assembly for RA treatment. METHODS: The synthetic gambogic acid dimers (GBA(2)) were self-assembled into NPs using a one-step solvent evaporation method. The size distribution, morphology, drug-loading efficiency (DLE) and storage stability were evaluated. A molecular dynamic simulation was conducted to gain further insight into the self-assembly mechanisms of GBA(2)/NPs. Besides, we investigated the cytotoxicity, apoptosis and cellular uptake profiles of GBA(2)/NPs in macrophages and osteoclasts. Finally, the specific biodistribution on the ankles of adjuvant-induced arthritis (AIA) mice, and the anti-RA efficacy of the AIA rat model were assessed. RESULTS: GBA(2)/NPs exhibited the uniform spherical structure, possessing excellent colloidal stability, high self-assembly stability, high drug loading and low hemolytic activity. Comparing with GBA, GBA(2)/NPs showed higher cytotoxicity, cellular uptake and apoptosis rate against osteoclasts. In addition, GBA(2)/NPs exhibited much higher accumulation in ankle joints in vivo. As expected, the systematic administration of GBA(2)/NPs resulted in the greater alleviation of arthritic symptoms, cartilage protection, and inflammation, notably the reduced systemic toxicity compared to free GBA. CONCLUSION: GBA(2)/NPs formed GBA dimers exhibited the superior accumulation in the inflamed joint and anti-RA activity, potentially attributing to the similar extravasation through leaky vasculature and subsequent inflammatory cell-mediated sequestration (“ELVIS”) effects in inflamed joint and the enhanced cellular uptake in macrophages and osteoclasts. Our findings provide substantial evidence that self-assembly of GBA(2)/NPs would be a promising therapeutic alternative for RA treatment. Dove 2023-09-22 /pmc/articles/PMC10522496/ /pubmed/37771407 http://dx.doi.org/10.2147/IJN.S422096 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Yuling
Nie, Xin
Wu, Yihan
Lin, Longfei
Liao, Qian
Li, Jingjing
Lee, Simon Ming-Yuen
Li, Hui
Zhang, Jinming
Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title_full Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title_fullStr Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title_full_unstemmed Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title_short Carrier-Free Gambogic Acid Dimer Self-Assembly Nanomedicines for Rheumatoid Arthritis Treatment
title_sort carrier-free gambogic acid dimer self-assembly nanomedicines for rheumatoid arthritis treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522496/
https://www.ncbi.nlm.nih.gov/pubmed/37771407
http://dx.doi.org/10.2147/IJN.S422096
work_keys_str_mv AT liuyuling carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT niexin carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT wuyihan carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT linlongfei carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT liaoqian carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT lijingjing carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT leesimonmingyuen carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT lihui carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment
AT zhangjinming carrierfreegambogicaciddimerselfassemblynanomedicinesforrheumatoidarthritistreatment